Solid Tumor
34 competing products in clinical development for Solid Tumor.
Pipeline by Phase
Phase 130
Phase 1/23
Phase 21
All Products (34)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Farletuzumab ecteribulin + Prednisone + Prednisolone + Dexamethasone + Lenvatinib | Eisai | Phase 1/2 | Recruiting | 39 |
| ROSE12 + Atezolizumab | Chugai Pharmaceutical | Phase 1 | Recruiting | 36 |
| ASP5834 + panitumumab | Astellas Pharma | Phase 1 | Recruiting | 36 |
| Setidegrasib + Cetuximab + Leucovorin + Oxaliplatin + Fluorouracil + Irinotecan + Nanoparticle albumin-bound-paclitaxel + Gemcitabine + Docetaxel + Pembrolizumab + Cisplatin + Carboplatin + Pemetrexed + Liposomal Irinotecan | Astellas Pharma | Phase 1 | Recruiting | 36 |
| ONO-7428 | Ono Pharmaceutical | Phase 1 | Recruiting | 36 |
| Cetuximab + Carboplatin + 5 - FU | Eli Lilly | Phase 2 | Completed | 35 |
| DS-1055a | Daiichi Sankyo | Phase 1 | Active | 33 |
| ASP4396 | Astellas Pharma | Phase 1 | Active | 33 |
| E7389-LF | Eisai | Phase 1 | Active | 33 |
| Mogamulizumab + Nivolumab | Kyowa Kirin | Phase 1/2 | Completed | 32 |
| LY3300054 + Ramucirumab + Abemaciclib + Merestinib + LY3321367 | Eli Lilly | Phase 1 | Completed | 29 |
| SAIL66 | Chugai Pharmaceutical | Phase 1 | Completed | 29 |
| PLX3397 | Daiichi Sankyo | Phase 1 | Completed | 29 |
| DS-7423 | Daiichi Sankyo | Phase 1 | Completed | 29 |
| ASP3026 | Astellas Pharma | Phase 1 | Completed | 29 |
| lenvatinib | Eisai | Phase 1 | Completed | 29 |
| MORAb-004 | Eisai | Phase 1 | Completed | 29 |
| E7050 | Eisai | Phase 1 | Completed | 29 |
| KHK2455 + Mogamulizumab | Kyowa Kirin | Phase 1 | Completed | 29 |
| KW-2450 | Kyowa Kirin | Phase 1 | Completed | 29 |
| Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558) | Kyowa Kirin | Phase 1 | Completed | 29 |
| ONO-7913 | Ono Pharmaceutical | Phase 1 | Completed | 29 |
| ZN-c3 + Carboplatin + Pegylated liposomal doxorubicin + Paclitaxel + Gemcitabine + Bevacizumab | Zentalis Pharmaceuticals | Phase 1 | Recruiting | 26 |
| LY3435151 + Pembrolizumab | Eli Lilly | Phase 1 | Terminated | 21 |
| LY3415244 | Eli Lilly | Phase 1 | Terminated | 21 |
| ASP1012 + Pembrolizumab | Astellas Pharma | Phase 1 | Terminated | 21 |
| ONO-7914 + ONO-4538 | Ono Pharmaceutical | Phase 1 | Terminated | 21 |
| ONO-7579 | Ono Pharmaceutical | Phase 1 | Terminated | 21 |
| ATOR-1017 | Alligator Bioscience AB | Phase 1 | Completed | 19 |
| ATOR-1015 | Alligator Bioscience AB | Phase 1 | Completed | 19 |
| NL-201 + Pembrolizumab Injection [Keytruda] | Neurogene | Phase 1 | Completed | 19 |
| Azenosertib | Zentalis Pharmaceuticals | Phase 1 | Completed | 19 |
| ALG.APV-527 | Alligator Bioscience AB | Phase 1/2 | UNKNOWN | 18 |
| BBI-825 | Boundless Bio | Phase 1 | Terminated | 11 |